Halozyme Therapeutics (HALO) reported Q2 non-GAAP earnings late Thursday of $2.28 per diluted share, up from $1.54 a year earlier.
Analysts polled by FactSet expected $1.79.
Revenue in the three months ended June 30 rose to $481 million from $325.7 million a year earlier.
Analysts projected $402.3 million.
The company increased full-year guidance to adjusted EPS of $8.65 to $9 on revenue of $1.835 billion to $1.91 billion. The prior outlook was EPS of $7.75 to $8.25 on revenue of $1.71 billion to $1.81 billion.
Analysts project EPS $7.94 on revenue of $1.77 billion.
Halozyme shares rose 4.9% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments